NASDAQ · Biotechnology

PRQR (PRQR) Stock

$1.88 -1.32% NASDAQ: PRQR Healthcare

Valuation

MetricValue
Price$1.88
Market Cap$197.45M
P/E Ratio-2.29
P/B Ratio2.84
P/S Ratio10.51
EPS (TTM)$-0.64
52-Week High$3.10
52-Week Low$1.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-78.07%
ROA-23.07%
ROCE-84.00%
Gross Margin89.75%
Operating Margin-3.46%
Net Margin-3.39%
Debt/Equity0.36
Current Ratio3.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$4.0M$7.0M$19.0M$15.0M
Operating Profit$-57.0M$-65.0M$-32.0M$-30.0M$-42.0M
Net Profit$-61.0M$-64.0M$-28.0M$-28.0M$-41.0M
EPS$-0.96$-0.91$-0.35$-0.34$-0.38
Op Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$210.0M$171.0M$152.0M$168.0M$113.0M
Total Liabilities$96.0M$105.0M$107.0M$79.0M$63.0M
Cash$188.0M$95.0M$131.0M$149.0M$92.0M
Borrowings$60.0M$22.0M$22.0M$17.0M$14.0M

Latest News

Daily – Vickers Top Buyers & Sellers for 07/14/2026 Argus Research · Jul 14, 2026 ProQR Registers Shares for Resale by Investor MT Newswires · Jul 6, 2026 Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating MT Newswires · Jun 26, 2026 ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint MT Newswires · Jun 25, 2026 ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering MT Newswires · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-69.0M$22.0M$-36.0M$-51.0M
Investing Cash Flow$-1.0M$-1.0M$3.0M$-5.0M$-2.0M
Financing Cash Flow$2.0M$0$0$0$0
Net Cash Flow$112.0M$-93.0M$24.0M$30.0M$-39.0M
Free Cash Flow$-26.0M$-69.0M$20.0M$-38.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-1.90
FCF Yield-34.69%
Quick Ratio2.48
Interest Coverage-42.00
Return 1Y-31.45%
Return 3Y-2.86%
Return 5Y-69.26%

Ownership

Insiders Held14.22%
Institutions Held38.63%
Institutions Float Held45.03%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.6,253,4672026-03-31
Privium Fund Management B.V.5,467,1492026-03-31
Aberdeen Group plc3,316,9652026-03-31
Affinity Asset Advisors, Llc2,454,2782026-03-31
Sio Capital Management, LLC1,954,7152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About PRQR

PRQR is led by CEO Daniel Anton de Boer, publicly traded since 2014.

PRQR stock trades at $1.88 with a market capitalization of $197.45M. The stock is valued at a price-to-earnings (P/E) ratio of -2.29, price-to-book of 2.84, price-to-sales of 10.51. Over the past 52 weeks the stock has ranged between $1.33 and $3.10, and currently trades 39.4% below its 52-week high.

On profitability, PRQR generates a return on equity (ROE) of -78.07%, return on capital employed of -84.00%, an operating margin of -3.46%, a net profit margin of -3.39%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides